SpyGlass Pharma, Inc.
SGP
$24.48
$0.341.41%
NASDAQ
| 12/31/2025 | |||||
|---|---|---|---|---|---|
| Revenue | -- | ||||
| Total Other Revenue | -- | ||||
| Total Revenue | -- | ||||
| Cost of Revenue | -- | ||||
| Gross Profit | -- | ||||
| SG&A Expenses | 194.08% | ||||
| Depreciation & Amortization | -- | ||||
| Other Operating Expenses | -- | ||||
| Total Operating Expenses | 75.76% | ||||
| Operating Income | -75.76% | ||||
| Income Before Tax | -49.48% | ||||
| Income Tax Expenses | -- | ||||
| Earnings from Continuing Operations | -49.48% | ||||
| Earnings from Discontinued Operations | -- | ||||
| Extraordinary Item & Accounting Change | -- | ||||
| Minority Interest in Earnings | -- | ||||
| Net Income | -49.48% | ||||
| EBIT | -75.76% | ||||
| EBITDA | -75.39% | ||||
| EPS Basic | -24.90% | ||||
| Normalized Basic EPS | -24.90% | ||||
| EPS Diluted | -24.32% | ||||
| Normalized Diluted EPS | -24.90% | ||||
| Average Basic Shares Outstanding | 19.68% | ||||
| Average Diluted Shares Outstanding | 19.68% | ||||
| Dividend Per Share | -- | ||||
| Payout Ratio | -- | ||||